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LETTER
NOTES & COMMENTSResponse to ‘‘Linear IgA bullous
dermatosis protracted by
vancomycin-loaded bone cement’’Fig 1. Erosions and bullae on the trunk.To the Editor: We read with great interest the case
report by Nartker et al1 on linear IgA bullous disease
(LABD) associated with vancomycin-loaded bone
cement. We report a similar case to further highlight
this entity, as we suspect it is underreported and
likely to be an increasing issue given our aging
population.
A 64-year-old man was admitted for a revision of a
left total knee replacement. He went on to have
widespread bullae and erosions over the trunk
(Fig 1), limbs, scalp and mucosa 7 days postproce-
dure. Interestingly, there was a linear distribution of
blisters around the dressing sites (Fig 2) suspicious of
a contact allergy. He had been fitted with a
vancomycin-impregnated cement spacer (VICS)
and was receiving intravenous vancomycin post-
operatively. Bacterial and virology swabs from the
blister lesions were negative. Skin biopsy found
subepidermal blistering with eosinophil and
neutrophil-rich inflammation. Direct immunofluo-
rescence illustrated linear IgA deposition indicating
LABD.
Vancomycin was switched to teicoplanin given
the possibility of a drug-related blistering disorder.
Prednisolone (40 mg once daily) was commenced
with application of clobetasol propionate 0.05%
ointment and regular emollients. Significant
improvement of the skin was observed, and he was
subsequently discharged and seen in dermatology
outpatient clinic 3 weeks later. He continued to have
new blisters; therefore, oral dapsone (100 mg once
daily) was introduced alongside prednisolone.
Dapsone was later increased to 125 mg and prednis-
olone gradually tapered.
At 3 months there was marked improvement with
clear skin and no new blister formation; thus,
prednisolone was withdrawn successfully. Patch
testing was performed to exclude a possibility of
contact allergy to the dressings given the initial blister
development around the left knee dressing site.
Standard and dressing series in concordance to the
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904 OCTOBER 2019which revealed negative results. After 12 months,
dapsone and topical steroids were all discontinued,
as satisfactory disease control was achieved. In the
interim, the patient had another revision procedure
of the left knee without vancomycin with no
dermatologic complications.
This is another case reporting LABD with VICS.
The patient did initially respond well to the oral
corticosteroids and cessation of intravenous vanco-
mycin. However, the formation of new blisters
would support vancomycin being absorbed system-
ically from the cement spacer. It is noted that there is
an increasing use of antibiotic-impregnated cement
spacer to minimize periprosthetic infection in joint
replacement surgery. Concurrently, there have been
growing reports of linear IgA bullous dermatosis
associated with VICS.2,3 Recognition of this potential
link is crucial in any presentation of blistering
disorder seen in those who have received parenteral
vancomycin and VICS, as we may see more cases in
the future. Lastly, LABD associated with vancomycin
has been reported to exhibit isomorphic phenome-
non which can mimic a contact dermatitis as in our
case.4 This finding is clinically important for dressing
use and mobilization postprocedure, as this couldJ AM ACAD DERMATOL
Fig 2. Isomorphic reaction around the dressing site.
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effective counselling prior to discharge.
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